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in vivo and reduces the liver metastasis in
metastatic form of mouse breast cancer
Mohammad Hossein Yazdi1, Mehdi Mahdavi2, Neda Setayesh1, Mohammad Esfandyar1
and Ahmad Reza Shahverdi1*Abstract
Background and the purpose of the study: Selenium enriched Lactobacillus has been reported as an
immunostimulatory agent which can be used to increase the life span of cancer bearing animals. Lactic acid
bacteria can reduce selenium ions to elemental selenium nanoparticles (SeNPs) and deposit them in intracellular
spaces. In this strategy two known immunostimulators, lactic acid bacteria (LAB) and SeNPs, are concomitantly
administered for enhancing of immune responses in cancer bearing mice.
Methods: Forty five female inbred BALB/c mice were divided into three groups of tests and control, each
containing 15 mice. Test mice were orally administered with SeNP-enriched Lactobacillus brevis or Lactobacillus
brevis alone for 3 weeks before tumor induction. After that the administration was followed in three cycles of seven
days on/three days off. Control group received phosphate buffer saline (PBS) at same condition. During the study
the tumor growth was monitored using caliper method. At the end of study the spleen cell culture was carried out
for both NK cytotoxicity assay and cytokines measurement. Delayed type hypersensitivity (DTH) responses were also
assayed after 72h of tumor antigen recall. Serum lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) levels
were measured, the livers of mice were removed and prepared for histopathological analysis.
Results: High level of IFN-γ and IL-17 besides the significant raised in NK cytotoxicity and DTH responses were
observed in SeNP-enriched L. brevis administered mice and the extended life span and decrease in the tumor
metastasis to liver were also recorded in this group compared to the control mice or L.brevis alone administered
mice.
Conclusion: Our results suggested that the better prognosis could be achieved by oral administration of
SeNP-enriched L. brevis in highly metastatic breast cancer mice model.
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Using the immunomodulatory agents in the field of can-
cer treatment has a growing trend during last decades
[1,2]. This strategy is also known as adjuvant therapy
and some studies have demonstrated the advantages of
this strategy for cancer treatment [3]. Immunomodulatory
agents are divided in two groups of immunosupressors
and immunostimulators. Chemical immunomodulators
like levamizole have been used in order to stimulate
immune response against cancer and AIDS [4]. Natural
immunomodulators like glucan or other oligosaccharide
components which are mostly derived from microbial
source are being applied to stimulate the immune re-
sponse against cancers [5].
Lactic acid bacteria (LAB) are Gram positive normal
flora which shows variety of beneficial effects on their
host’s health including the prevention of tumor growth
[6]. Many studies which include the effects of orally ad-
ministered lactobacilli and bifidobacteria on the immune
system have been performed in animal models (e.g.,
tumor, infection, and allergy models) [7,8]. An increase
in natural killer (NK) cell activity was observed in mice
which were administered orally with some strains of
LAB [9]. The activation of the systemic and secretary
immune response by LAB requires many complex inter-
actions among the different constituents of the intestinal
ecosystem (microflora, epithelial cells and immune cells).
It also seems that some of these immunological effects
may be related to the cell components of LAB bacteria
[10]. As many studies have demonstrated it is notably
interesting that immune system can be optimized
through oral supplementation of specific Lactobacillus
strains [11,12]. Depending on their intuitive properties,
orally applied lactobacilli have been reported to affect
T-helper 1 and T-helper 2 pathways by local cytokine
production in the gut and systemic specific antibody
formation [13,14].
On the other hand selenium (Se), as an essential
micronutrient element which exhibit anticarcinogenic
effects, can prevent the transformation of normal cells
to malignant cells and the activation of oncogenes in
transformed cells [15,16]. Consumption of Se affects the
development and expression of nonspecific, humoral,
and cell-mediated immune responses and deficiency in
Se appears to result in immunosuppression, whereas
supplementation with low doses of Se appears to result
in augmentation or restoration of immunologic func-
tions [17]. SeNP-enriched Lactobacillus can be consid-
ered as a new form of Se organic products. Recently we
reported the effect of SeNP-enriched Lactobacillus
plantarum on the immune response and lifespan of 4T1
breast cancer bearing mice and show this can increase
host immune response (i.e. NK cell cytotoxicity) and
enhanced the survival rate of animals for 130 days [18].To obtain a better survival rate, in the current study we
isolated and characterized another immunostimulant
lactic acid bacterium (Lactobacillus brevis) and used for
intracellular reduction of Se ions. These SeNP-enriched
probiotic has been administered in mice bearing 4T1
breast cancer tumor and the effect of this administration
on the survival of cancerous animals, immune responses
and liver metastasis was compared to L. brevis alone.
Materials and methods
Animals
Forty five female inbred BALB/c mice with six to eight
weeks old and each weighing from 25 to 30 g, were pur-
chased from the Pasture Institute of Iran (Tehran, Iran).
They were divided into three groups of test and control,
each containing 15 mice. The mice were kept in plastic
cages, allowed free access to water, and maintained on a
12:12 h light and dark cycle during the study period.
The temperature and humidity were controlled at 23 ±
1°C and 55 ± 10%, respectively, and all mice were fed via
a standard mouse pellet diet. The control mice in this
study were kept separated from the test group, but at
the same temperature and humidity, and they were fed
the same food.
Lactobacillus isolation and characterization
The Lactobacillus bacterium was isolated from human
feces and characterized by 16s rDNA sequence analysis
[19]. Genomic DNA was extracted from bacterial cells
using PrimePrep Genomic DNA isolation kit according
to the manufacturer’s instructions. It was then subjected
to PCR amplification using universal primers 27F (5′ GA
GTTTGATCCTGGCTCAG-3′) and 1492R (5′-GGTTA
CCTTGTTACGACTT-3′) targeting the conserved re-
gions of bacterial 16S ribosomal RNA gene. The amplifi-
cation program consisted of one cycle of 94°C for 3 min;
30 cycles of 94°C for 20 s, 55 for 30 s, and 72°C for 2 min;
and finally one cycle of 72°C for 5 min. The amplified
DNA fragment was purified from 1% agarose gel using the
QIAquick Gel Extraction Kit (Qiagen, USA) according to
the supplier's instructions and was sent for automated
sequencing using the above primers (GenFanAvaran Co.,
Iran). Sequence similarity searches were done with the
BLAST database (National Center for Biotechnology
Information), and the sequence was submitted to GenBank.
Preparation of SeNP-enriched and non-enriched
probiotics
The isolated LAB bacterium which was identified as
Lactobacillus brevis was inoculated into 10 ml of
DeMan–Rogosa–Sharpe (MRS) broth (Merck, Germany)
and cultivated overnight at 37°C under anaerobic condi-
tions. One mL of a stock solution of SeO2 (254 mM)
was then added to 100 ml of Lactobacillus broth culture
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(corresponding to a 2.54 mM solution of SeO2), and
incubation at 37°C was continued for 72h. During this
time, the Se ions were reduced to form intracellular red
elemental selenium. The bacteria were then collected by
centrifugation at 4000 × g for 30 min at 4°C, washed
three times with sterile phosphate buffer saline (PBS),
and used for the animal study.
Animal study
The SeNP-enriched L. brevis alone was separately
re-suspended in PBS solutions to obtain the desired bac-
terial cell concentration of 2.7 × 108 CFU/ml. 0.5 ml of
this suspension (containing about 100 μg/ml of Se ions)
was orally administered to the mice by using a standard
gastric feeding gavage as follows:
The test group of mice was daily administered with
0.5 ml of SeNP-enriched L. brevis suspension for three
consecutive weeks prior to tumor challenge. This daily
feeding was continued for three repeated cycles of seven
days on/three days off. Same above protocol was also
concomitantly repeated for L .brevis alone. Also the
control mice (PBS-received mice) were given an equal
volume of PBS solution in a similar procedure.
Tumor challenge
The 4T1 cell line ATCC CRL-2539 (originated from
mice breast tumor and is routinely applied to simulate
the end stage of human breast cancer in animal model)
was used for the induction of tumors in inbred Balb/c
mice. For this purpose, 200 μl of RPMI, containing 4T1
cells at a concentration of 1 × 106 cell/ml, was injected
subcutaneously near the mammary glands of female
mice. All mice were followed until a tumor nodule was
observed (10 days after injection).
The tumor growth measurement
Tumor growth was measured twice during this study
firstly when tumors became palpable and at last before
mice scarification by caliper measurement of the tumor
length in two different dimensions. The tumor volumes
of 15 mice in each test and control groups were deter-
mined using the formula: V = 0.5×d2×D [20] where V is
the tumor volume (mm3), d is the shorter diameter, and
D is the longer diameter. Finally average tumor volumes
of last time measurement were subtracted from the first
time and reported as related tumor volume.
Providing the tumor antigen
The tumor antigen was prepared from the tumor of one
of the mice. The tumor was removed from the body,
dissected into small sections (1 mm3), and homogenized
in sterile PBS. This homogenized sample was washed
with sterile PBS, 100 μl/ml of PMSF was added to inhibitthe endogenous proteases, and the sample was sonicated
(Hielscher Ultrasonics GmbH, Germany) for 10 minute.
The sample was then dialyzed against 1000 ml of PBS
buffer for 24 h at 4°C using a cellulose membrane with a
14 kD cutoff (Sigma, Germany) and the PBS was
changed every eight hours. After dialysis, the concen-
trated sample was collected and the protein concentra-
tion was determined using the conventional Bradford
method. The sample was used to stimulate splenocytes
in the cytokine production tests and delayed type hyper-
sensitivity response (DTH) assay.
Evaluation of DTH response
The DTH response was measured according to a method
described by Jin et al. [21]. Briefly, 30 days after tumor
challenge, 7 mice from each group were challenged with
the tumor antigen (20 μg) in the left footpad and with the
PBS in the right footpad. Footpad induration was mea-
sured at 72 h later using caliper measurements.
Cytokine determination in spleen cell culture
One month after tumor challenge, spleens of eight mice
from each group were removed aseptically and dissected.
Spleen cells were then prepared using an appropriate
nylon mesh screen and the remaining RBCs in the
spleen cell collection were disrupted with conventional
RBC lysis buffer. The spleen cell counts were adjusted to
2.5 × 106 cell/ml in RPMI1640 (Gibco Life Technologies,
Germany) supplemented with 10% fetal bovine serum
(Invitrogen, Paisley Germany), 100 μg/ml streptomycin,
and 100 IU/ml penicillin (Sigma, Germany). These cells
were then stimulated with 20 μg/ml of the tumor anti-
gen (the amount was determined in a previous study)
for 72 h [4] at 37°C in a humidified atmosphere of 5%
CO2. The levels of IL-17 and IFN-γ in the spleen cell
culture supernatants were determined using ELISA kits
(R&D Systems, Minneapolis, MN), according to the
manufacturer’s instructions. The limit of detection for
IFN-γ was 2 pg and for IL-17 was 5 pg.
Natural killer cell activity by LDH assay
The NK cell activity was evaluated in eight mice from
each group (these mice were also used for the cytokine
determination test). An aliquot containing 2.5 × 106 sple-
nocytes was removed and mixed with target K562 cells
at a ratio of 1:100 (Target:Effector) in 96-well culture
plates with U-shaped bottoms (Corning, Corning, NY)
in 0.2 ml of RPMI1640 containing 2% BSA. The release
of LDH was measured using an LDH assay kit (Takara,
Japan) by first gently centrifuging the plates for 5 min at
250 × g and then incubating them for four h at 37°C in
5% CO2. After incubation, the plates were centrifuged
for 10 min at 250 × g, and the supernatant was trans-
ferred from each well of the culture plate to the
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microliters of reaction solution (prepared according to
the kit instructions) was then added to each well, and
the plate was incubated with gentle shaking on an
orbital shaker for 30 min. The absorbance of each well
was then read at 490 nm. The specific release of LDH
was calculated as a percentage using the following
formula [22]:
Experimental value−low control=highcontrol−lowcontrol  100
LDH and ALP determination in blood circulation
Blood was collected from pre-orbital cavity of eight mice
from each group (these mice were also used for spleen
cell culture). Each mouse was placed under the
anesthesia induced by ether and the blood samples (one
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Figure 1 Related tumor volume in tumor-bearing mice which
received SeNP-enriched L. brevis, L. brevis alone and PBS buffer
(control group). Tumor growth was measured twice a week and
evaluated by caliper measurement of the tumor length. The tumor
related volume which refers to the measurement of 15 tumors in each
group was achieved by subtraction of first measurement from the
latest. Asterisks indicate statistical significance (P≤ 0.05 significance).appropriate microtubes. Serum samples were prepared
by storing the blood at 4°C for one hour, and the
resulting coagulated blood cells were then separated
from the serum by centrifugation for 20 min at 4000 × g.
The serum was transferred to a new microtube, and the
lactate dehydrogenase (LDH) and alkaline phosphatase
(ALP) levels in each sample was determined using the
IFCC method [23,24].
Histopathological studies
After cervical dislocation of experimental mice (these
mice were also used for spleen cell culture) the liver was
taken for histopathological analysis. Tissues were fixed
in 10% formalin in PBS solution, in embedded paraffin,
and cut into 3-5-μm thick sections. The sections were
stained with hematoxylin eosin for general analysis using
light microscope with 400× magnification. Pathological
assay was done after preparation of H&E stained slides
from tumor and liver tissues. In next step, the 10 micro-
scopic fields in each slide were carefully observed and




















Figure 2 Foot pad induration in tumor-bearing mice which
received SeNP-enriched L. brevis, L. brevis alone and PBS buffer
(control group). Footpad induration was measured at 72 h after
tumor antigen re-challenge using caliper measurements.
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selected fields.Survival rate
At the end of the study period (one month after tumor
challenge), seven mice from each group (these mice were
also used for the DTH assay) were kept in standard con-
ditions and fed with standard diet, with free access to
water, and maintained under a 12:12 h light dark cycle
until they died. Daily deaths were recorded; after the last
death in both groups, the data were analyzed with a
Kaplan-Meier test.Statistical analysis
All of the statistical analyses, except for survival rate,
were conducted using SPSS software (Version 15.0) and
ANOVA tests. The survival rate data were analyzed by
the Kaplan-Meier test using also SPSS software (Version
15.0). The values are presented as mean ± SD.Ethical approval
The experimental procedures carried out in this study
were in compliance with the guidelines of the Tehran
University of Medical Science (Tehran, Iran) for the care






















Figure 3 Inductions of IFN-γ (left illustration) and IL17 (right illustrati
culture. The spleen cells were stimulated with tumor antigen for 72 h and
determined by ELISA. Data represent the means ± standard deviations for tResults
Identification of the microorganism
BLAST search of the 16S rDNA sequence against the
NCBI Nucleotide database was conducted for identifica-
tion of isolate. Alignment results containing 180 charac-
ters revealed 100% identity with L. brevis. The 16S rRNA
gene sequence of the L. brevis isolate has been submitted
to GenBank under accession number JX966418.The tumor volumes growth measurement and DTH
response
Tumor growth was evaluated by twice-weekly caliper
measurements of the tumors from 15 mice from each
group. The tumor volume was calculated as described in
the Materials and Methods section. Data analysis
showed a significant (P ≤ 0.05) decrease in the growth
rate of tumors in the test mice when compared to the
control mice (Figure 1). The tumor mass has been en-
larged to 1550 mm3 in control mice while in test groups,
which received SeNP-enriched L. brevis or L. brevis
alone, the tumor volumes were decreased to 890 and
950 mm3, respectively. Also the antigen-specific Th1
recalling response was assessed by evaluating the DTH
reaction in the tumor antigen rechallenged mice. Also as
mentioned before, these mice were challenged with



















on) by administration of SeNP-enriched L. brevis in a spleen cell
then the levels of IFN-γ and IL-17 in the culture supernatants were
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Figure 4 NK cell activity in spleen cell cultures measured by
the LDH assay. A culture of 2.5 × 106 cells/well from the splenocytes
was added to K562 cells at a 1:100 ratio (Effector: Target ratio) and
plates were gently centrifuged for five min at 50 × g, then cultured in
RPMI1640 containing 10% FBS. The plates were incubated for seven
h at 37°C in 5% CO2 and the specific release of LDH was calculated
as a percentage. A significant increase * * * (P ≤ 0.001) in the NK
cytotoxicity was observed for the SeNP-enriched L. brevis group
compared to the control group. The data are the means ± SD of
triplicate cultures. SeNP-enriched L. brevis = selenium nanoparticle
enriched Lactobacillus brevis.
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results showed a greater swelling and thickness in the left
footpad 72h after the tumor antigen challenge in the test
group which received SeNP-enriched L. brevis compared
with the other groups (Figure 2). In contrast, no significant
increase in DTH response was observed in those test mice
which received L. brevis alone compared to control mice.
It may show that the prescription of L. brevis alone could
not significantly enhance the Th1 recalling response.
Cytokine determination in spleen cell culture
The levels of IFN-γ and IL-17 in the spleen cell culture
supernatants were measured using a sandwich ELISA
assay (R&D Systems, Minneapolis, MN). As shown in
right illustration of Figure 3, the level of IFN-γ was
significantly higher in the test groups than in the control
group (P ≤ 0.05). The IL-17 level in the test groups was
also significantly elevated when compared to the control
level (Left illustration of Figure 3).
Natural killer cell activity by LDH assay
We investigated and compared the effects of administra-
tion of SeNP-enriched L. brevis and L. brevis alone on
NK cells by using K562 cells as target cells and evaluat-
ing the release of LDH from these cells after 4 h of
exposure to the NK cells that were present among the
harvested splenocytes. The mice treated with SeNP-
enriched L. brevis showed a significantly increased level
of NK cell activity (P ≤ 0.001) compared to other groups
(Figure 4) which received probiotic alone or PBS solu-
tion (control mice).
Serum levels of LDH and ALP
Analysis of serum showed a decrease in the levels of
LDH and ALP in the mice which received SeNP-
enriched L. brevis when compared to the other groups
received L. brevis alone or PBS solution (control mice).
The decrease in serum LDH may have directly contrib-
uted to the decrease in the rate of tumor development
and tumor cell division in the groups treated by SeNP-
enriched L. brevis or L. brevis alone (left illustration of
Figure 5). Also the decrease in the ALP level in test mice
shows better liver prognosis in both treated groups com-
pared to control group (right illustration of Figure 5).
Histopathological studies
As it observes in left illustration of Figure 6 the rate of
tumor necrosis in test mice which received SeNP-
enriched L. brevis was considerably increased in com-
parison to other test or control groups. On the other
hand the highest decreasing rate in the level of liver
metastasis was diagnosed in histopathological slides
(Figures not shown) prepared from liver tissue of micewhich received SeNP-enriched L. brevis (right illustra-
tion of Figure 6).
Survival rate
The results of survival analysis in Figure 7 show the
decrease in the rate of mortality among the SeNP-enriched
L. brevis administered mice group in comparison to other
groups. In the test group which received SeNP-enriched
L. brevis, it was observed a remarkable decrease in mortal-
ity rate and indicated that administration of this formula-
tion could enhance the survival rate of tumor bearing mice
over 230 days period. The effect of L. brevis without SeNPs
was also investigated on the survival rates of tumor bearing
mice. Oral administration of L. brevis alone also enhanced
the survival rate of 4T1 tumor bearing mice over 75 days
































































Figure 5 Differences between the levels of ALP and LDH in the serum of mice, measured using the conventional IFCC method. Data are
shown in the range of U/L.
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enriched L. brevis (230 days). This result even is more
considerable than the survival time of cancerous mice
which received purified biogenic SeNPs (90 days) [25]
or SeNP-enriched L. plantarum (130 days) [18].
Discussion
Tumor development in cancer patients has been reported




























Figure 6 The levels of tumor necrosis (left illustration) and liver meta
slides prepared from tissue samples removed mice which received Sepatients [26]. Also routine chemotherapy and irradiation
treatment can considerably decrease the host immunity
and are main reasons to weak immune system in cancer
bearing patients [27] attenuate immunological response in
cancer bearing patients. It also weakens the natural
defense against foreign threats such as pathogenic or
opportunistic microorganisms. Therefore using some
immunomodulatory agents in immunosuppressed patients



















































Received Se NPs -enriched L. brevis
Received L. brevis alone
Received PBS buffer (Control)
Figure 7 Survival rates of mice administered SeNP-enriched L. brevis and L. brevis alone when compared with control mice at the end of
the study. A total of seven mice from each experimental group were kept under standard conditions until they died. The rate of death was
registered every day and the obtained data were analyzed with a Kaplan-Meier test after the last death in both test and control groups. The
lifespans of animals that received SeNP-enriched L. brevis or L. brevis alone were considerably increased compared to the lifespans of control mice.
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diseases. On the other hand, metastasis is major cause of
death among cancer bearing patient and can worsen the
prognosis of cancer especially for those who are suffering
from advanced level of cancer.
Recently we reported the immunostimulatory effect
of purified biogenic SeNPs [25] and SeNP-enriched
L. plantarum on the life span of 4T1 breast cancer
animal model [18]. Both formulations have increased
the survival rate of cancerous animals but the effect of
SeNP-enriched L. plantarum on the survival rate of
4T1 cancer bearing mice was more remarkable than
purified biogenic SeNPs or L. plantarum alone [18].
Oral administration of SeNP-enriched L. plantarum de-
layed the mortality of some cancerous animals for 130
days which was 40 days longer than the survival time of
animals received purified biogenic SeNPs. Although the
immunomodulatory effect of LAB is currently estab-
lished [28,29] but still it should not be ignored that this
effect is variable in different species of these bacteria
[30]. So the oral supplementation with other SeNPs
LAB strain may lead to obtain a better survival rate in
cancerous animals. Regarding to above fact, in this
study another strain of LAB was isolated from human
feces and identified as L. brevis. In next step this bacter-
ium was enriched by elemental Se and used for oral
supplementation of breast cancer bearing animals.
Then the effect of this type of supplementation and
supplementation of L. brevis alone on the immune re-
sponses and the liver metastasis have been investigated
and compared in breast cancer bearing animals.
SeNP-enriched Lactobacillus is an organoselenium
agent and a new form of Se which is synthesis and accu-
mulated in intracellular space of bacteria, this form of Sealso considered as biogenic SeNPs [31]. Although results
of some studies implied to the protective effect of Se
enriched lactobacillus on the CCL4 liver injury but as a
best of the authors’ knowledge it still no more under-
stood about immunostimulatory effect of this new form
of LAB [32]. Cytokine assay in the current study showed
an increase in the level of IFN-γ through the oral admin-
istration of SeNP- enriched L. brevis. On the other hand
IL-17 as another Th1 known cytokine also raised due to
this administration. Moreover, NK cell activity was
enhanced in the test mice which received SeNP-enriched
L. brevis and could be related to the increase in the level
of IFN-γ in some way.
NK cells play a major role in the rejection of tumors
and cells infected by viruses [32,33]. Also any decrease
in tumor volume occurred in SeNP-enriched L. brevis
administered mice can address to engaging of antitumor
immune responses such as NK cytotoxicity (Figure 4).
Enhancement of tumor necrosis as well as higher DTH
response in test mice which received SeNP- enriched
L. brevis can further confirm this hypothesis (Figure 2).
In the other hand, although the serum levels of aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) as two types of liver function enzymes were similar
in test and control groups (data are not shown) but
regarding to the result of histopathological study the tumor
metastasis into liver of SeNP-enriched L. brevis treated
mice was considerably lower than control group which
received PBS buffer. Moreover, it observed that by adminis-
tration of SeNP- enriched L. brevis the serum level of ALP
and LDH, which are considered for cancer monitoring,
have been reduced. Conclusively, the enhancement of life
span in SeNP- enriched L. brevis administered mice which
observed during this investigation as a promising result can
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future prevention and immunotherapy of cancer. But still
more studies are needed to develop this formula.
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